Skip to main content

Table 1 Associations of membranous ezrin expression with clinicopathological and investigative parameters in two independent patient cohorts of urothelial bladder cancer

From: Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts

   Cohort I (n = 100)   Cohort II (n = 342)
Factor n (%) Ezrin expression   n (%) Ezrin expression  
   median (range) p-value   median (range) p-value
Age       
≤ average 46 (46.9) 30.9 (0.0-100) 0.222 157 (45.9) 10.0 (0.0-100) 0.136
>average 54 (54.0) 35.0 (0.0-95.0)   185 (54.1) 10.0 (0.0-100)  
Gender       
Female 25 (25.9) 10.0 (0.0-90.0) 0.040 82 (24.0) 5.00 (0.0-90.0) 0.013
Male 75 (75.0) 40.0 (0.0-100)   260 (76.0) 10.0 (0.0-100)  
T-stage       
Ta 41 (41.0) 75.0 (0.0-100) <0.001 115 (33.6) 30.0 (0.0-100) <0.001
T1 22 (22.0) 25.0 (0.0-95.0)   116 (33.9) 10.0 (0.0-95.0)  
T2-3 37 (37.0) 2.0 (0.0-80.0)   111 (32.5) 0.0 (0.0-60.0)  
Grade       
Low 44 (44.0) 72.5 (0.0-100) <0.001 82 (24.0) 40.0 (0.0-100) <0.001
High 56 (56.0) 10.0 (0.0-90.0)   260 (76.0) 5.0 (0.0-95.0)  
PODXL expression       
Negative 78 (78.8) 40.0 (0.0-100) <0.001 306 (89.7) 10.0 (0.0-100) 0.009
Positive 21 (21.0) 5.00 (0–70.0)   35 (10.2) (0.0-0.80)